Literature DB >> 19701615

[Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008].

M E Beutel1, M Blettner, S Fischbeck, C Loquay, A Werner, H Marian.   

Abstract

BACKGROUND AND METHODS: Despite the increasing prevalence of malignant melanoma, psychosocial aspects have found little attention. A systematic review was conducted in order to identify psycho-oncological articles on patients with malignant melanoma.
RESULTS: Out of a total of 31 studies, 12 examine quality of life in malignant melanoma patients and 6 studies monitor quality of life in the course of therapy. Most studies originate from English-speaking countries (USA, UK, AU); few German studies have been published. Methodological limitations of the studies include cross-sectional assessment, unreported return rate, small sample sizes and comparability (heterogeneous or non-standardized psychosocial measures).
CONCLUSIONS: In addition to the tumor stage, psychosocial characteristics (coping with disease, social support) have a substantial effect on quality of life. Results from psychotherapy trials with malignant melanoma patients are encouraging. Given the overall high survival rates of malignant melanoma, quality of life and needs for care of long-term survivors need to be assessed.

Entities:  

Mesh:

Year:  2009        PMID: 19701615     DOI: 10.1007/s00105-009-1814-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  36 in total

1.  The role of religious and spiritual beliefs in coping with malignant melanoma: an Israeli sample.

Authors:  L Baider; S M Russak; S Perry; K Kash; M Gronert; B Fox; J Holland; A Kaplan-Denour
Journal:  Psychooncology       Date:  1999 Jan-Feb       Impact factor: 3.894

2.  [Patients' view of melanoma follow-up].

Authors:  Dorothée Nashan; Franz Kirschner; Gerhard Strittmatter; Frank Hirche; Peter Hensen; Carmen Loquai; Cornelia Mauch
Journal:  J Dtsch Dermatol Ges       Date:  2004-02       Impact factor: 5.584

3.  Prevalence and correlates of sun protection and skin self-examination practices among cutaneous malignant melanoma survivors.

Authors:  Sharon Manne; Stuart Lessin
Journal:  J Behav Med       Date:  2006-07-20

Review 4.  Follow-up in patients with localised primary cutaneous melanoma.

Authors:  Anne Brecht Francken; Esther Bastiaannet; Harald J Hoekstra
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

5.  Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon.

Authors:  Peter C Trask; Amber G Paterson; Peg Esper; Jason Pau; Bruce Redman
Journal:  Psychooncology       Date:  2004-08       Impact factor: 3.894

6.  Cognitive-behavioral intervention for distress in patients with melanoma: comparison with standard medical care and impact on quality of life.

Authors:  Peter C Trask; Amber G Paterson; Kent A Griffith; Michelle B Riba; Jennifer L Schwartz
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up.

Authors:  Fawzy I Fawzy; Andrea L Canada; Nancy W Fawzy
Journal:  Arch Gen Psychiatry       Date:  2003-01

8.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Authors:  M F Avril; S Aamdal; J J Grob; A Hauschild; P Mohr; J J Bonerandi; M Weichenthal; K Neuber; T Bieber; K Gilde; V Guillem Porta; J Fra; J Bonneterre; P Saïag; D Kamanabrou; H Pehamberger; J Sufliarsky; J L Gonzalez Larriba; A Scherrer; Y Menu
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

9.  Melanoma survivorship: research opportunities.

Authors:  Susan A Oliveria; Jennifer L Hay; Alan C Geller; Maureen K Heneghan; Mary S McCabe; Allan C Halpern
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

10.  Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.

Authors:  S Dixon; S J Walters; L Turner; B W Hancock
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

View more
  7 in total

1.  [Supportive therapy and management of side effects in dermato-oncology].

Authors:  Laura von Dücker; Svea Hüning; Katharina Kähler; Patrick Terheyden; Do Ro Thée Nashan
Journal:  Hautarzt       Date:  2019-12       Impact factor: 0.751

2.  [Psycho-oncological care for melanoma patients: conception and implementation].

Authors:  K Albrecht; F Meiss; T Zeiss; D Nashan; K Reuter
Journal:  Hautarzt       Date:  2013-12       Impact factor: 0.751

3.  Psychosocial Care Needs of Melanoma Survivors: Are They Being Met?

Authors:  Sabine Fischbeck; Barbara H Imruck; Maria Blettner; Veronika Weyer; Harald Binder; Sylke R Zeissig; Katharina Emrich; Peter Friedrich-Mai; Manfred E Beutel
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

4.  Determinants of illness-specific social support and its relation to distress in long-term melanoma survivors.

Authors:  Sabine Fischbeck; Veronika Weyer-Elberich; Sylke R Zeissig; Barbara H Imruck; Maria Blettner; Harald Binder; Manfred E Beutel
Journal:  BMC Public Health       Date:  2018-04-17       Impact factor: 3.295

5.  Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey.

Authors:  Theresa Steeb; Anja Wessely; Heike Merkl; Caroline Voskens; Michael Erdmann; Lucie Heinzerling; Carola Berking; Markus V Heppt
Journal:  Patient Prefer Adherence       Date:  2021-01-12       Impact factor: 2.711

6.  Screening for distress in routine oncological care-a survey in 520 melanoma patients.

Authors:  Carmen Loquai; Vera Scheurich; Nils Syring; Irene Schmidtmann; Stephan Rietz; Andreas Werner; Stephan Grabbe; Manfred E Beutel
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

7.  Outpatient Follow-up and Secondary Prevention for Melanoma Patients.

Authors:  Ryan G Gamble; Daniel Jensen; Andrea L Suarez; Anne H Hanson; Lauren McLaughlin; Jodi Duke; Robert P Dellavalle
Journal:  Cancers (Basel)       Date:  2010-06-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.